Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants

Virology

Volumn 285, Issue 2, 2001, Pages 193-203

  Dykes, Carrie ^a   Fox, Kora ^a   Lloyd, Amanda ^a   Chiulli, Michael ^a   Morse, Eugene ^b   Demeter, Lisa M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Compensatory mutations; Drug resistance; Human immunodeficiency virus type 1 (HIV 1); Nonnucleoside reverse transcriptase inhibitors (NNRTIs); Replication fitness; Reverse transcriptase

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MUTATION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035811838     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.0920     Document Type: Article

References (40)

1. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
2. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to non-nucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture
3. Human immunodeficiency virus type 1 mutations selected in patients failing efavirez combination therapy
4. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer
5. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population
6. HIV-1: Gambling on the evolution of drug resistance?
7. Effects of zidovudine-selected human immuno-deficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
8. Mutations in HIV reverse transcriptase which alter RNase H activity and decrease strand transfer efficiency are suppressed by HIV nucleocapsid protein
9. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
10. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
11. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
12. Improved envelope function selected by long-term cultivation of a translation-impaired HIV-1 mutant
13. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
14. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
15. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
16. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication
17. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
18. Viral quasispecies
19. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
20. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities
21. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
22. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
23. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
24. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy
25. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene
26. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
27. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
28. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
29. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy
30. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
31. ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team
32. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine
33. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
34. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
35. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
36. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1
37. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
38. Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma
39. Viral dynamics in human immunodeficiency virus type 1 infection
40. L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase